Results about: bone metastasis
Intricate signalling networks control cell division, differentiation, movement, organization and death. Understanding how cells read and transform these signals into changes in cell behaviour is a major research focus of our group.
The company concludes a 2.2 million € round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital and Fundación Vila Casas.
Inbiomotion, a spin off founded by IRB Barcelona's group leader, Roger Gomis, develops diagnostic products for predicting risks that cancer patients may suffer bone metastasis.
A study published today in the Journal of National Cancer Institute (JNCI) by ICREA researcher Roger Gomis may be key to the early detection of patients at risk of developing metastasis to the bone
This new knowledge may accelerate the development of the first preventive treatment of bone metastasis
Inbiomotion, an IRB Barcelona spin off company and financed with venture investors Ysios Capital, has already begun clinical trials